Growth hormone (GH) treatment reduces peripheral thyroid hormone action in girls with Turner syndrome

S. SUSPERREGUY, M. B. MIRAS, M. M. MONTESINOS, I. D. MASCANFRONI, L. MUÑOZ, G. SOBRERO, L. SILVANO, A. M. MASINI-REPISO, A. H. COLEONI, H. M. TARGOVNIK AND C. G. PELLIZAS

WILEY-BLACKWELL PUBLISHING, INC

Lugar: Londres; Año: 2007 vol. 67 p. 629 - 629

ummary Objective Turner syndrome (TS) is an indication for GH therapy in spite of the modest growth response. Somatic growth depends not only on GH insulin-like growth factor I (IGF-I) axis but also on thyroid hormone (TH) status. We have previously reported that supraphysio- logical IGF-I levels diminished TH actions in rat tissues by reducing the nuclear TH receptor (TR). GH treatment to TS patients induces high IGF-I levels and therefore a reduction of TH action in tissues may be expected. We aimed at evaluating the effect of GH therapy in TS girls on peripheral TH action. Design and patients We set up a reverse transcription-polymerase chain reaction (RT-PCR) for TR mRNA estimation in peripheral blood mononuclear cells (PBMC) and compared TR mRNA levels from 10 normal, 10 TS and 10 TS girls under GH therapy (0·33 mg/kg/week for 0·5?2 years). Measurements After RNA extraction from PBMC, TR and β -actin mRNAs were coamplified by RT-PCR. In addition serum biochemical